Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
13
05
2022
accepted:
02
12
2022
pmc-release:
01
05
2024
medline:
3
5
2023
pubmed:
8
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
T cells mediate pathogenic and reparative processes during AKI, but the exact mechanisms regulating kidney T cell functions are unclear. This study identified upregulation of the novel immune checkpoint molecule, TIGIT, on mouse and human kidney T cells after AKI. TIGIT-expressing kidney T cells produced proinflammatory cytokines and had effector (EM) and central memory (CM) phenotypes. TIGIT-deficient mice had protection from both ischemic and nephrotoxic AKI. Single-cell RNA sequencing led to the discovery of possible downstream targets of TIGIT. TIGIT mediates AKI pathophysiology, is a promising novel target for AKI therapy, and is being increasingly studied in human cancer therapy trials. T cells play pathogenic and reparative roles during AKI. However, mechanisms regulating T cell responses are relatively unknown. We investigated the roles of the novel immune checkpoint molecule T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) in kidney T cells and AKI outcomes. TIGIT expression and functional effects were evaluated in mouse kidney T cells using RNA sequencing (RNA-Seq) and flow cytometry. TIGIT effect on AKI outcomes was studied with TIGIT knockout (TIGIT-KO) mice in ischemia reperfusion (IR) and cisplatin AKI models. Human kidney T cells from nephrectomy samples and single cell RNA sequencing (scRNA-Seq) data from the Kidney Precision Medicine Project were used to assess TIGIT's role in humans. RNA-Seq and flow cytometry analysis of mouse kidney CD4+ T cells revealed increased expression of TIGIT after IR injury. Ischemic injury also increased TIGIT expression in human kidney T cells, and TIGIT expression was restricted to T/natural killer cell subsets in patients with AKI. TIGIT-expressing kidney T cells in wild type (WT) mice had an effector/central memory phenotype and proinflammatory profile at baseline and post-IR. Kidney regulatory T cells were predominantly TIGIT+ and significantly reduced post-IR. TIGIT-KO mice had significantly reduced kidney injury after IR and nephrotoxic injury compared with WT mice. scRNA-Seq analysis showed enrichment of genes related to oxidative phosphorylation and mTORC1 signaling in Th17 cells from TIGIT-KO mice. TIGIT expression increases in mouse and human kidney T cells during AKI, worsens AKI outcomes, and is a novel therapeutic target for AKI.
Sections du résumé
SIGNIFICANCE STATEMENT
T cells mediate pathogenic and reparative processes during AKI, but the exact mechanisms regulating kidney T cell functions are unclear. This study identified upregulation of the novel immune checkpoint molecule, TIGIT, on mouse and human kidney T cells after AKI. TIGIT-expressing kidney T cells produced proinflammatory cytokines and had effector (EM) and central memory (CM) phenotypes. TIGIT-deficient mice had protection from both ischemic and nephrotoxic AKI. Single-cell RNA sequencing led to the discovery of possible downstream targets of TIGIT. TIGIT mediates AKI pathophysiology, is a promising novel target for AKI therapy, and is being increasingly studied in human cancer therapy trials.
BACKGROUND
T cells play pathogenic and reparative roles during AKI. However, mechanisms regulating T cell responses are relatively unknown. We investigated the roles of the novel immune checkpoint molecule T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) in kidney T cells and AKI outcomes.
METHODS
TIGIT expression and functional effects were evaluated in mouse kidney T cells using RNA sequencing (RNA-Seq) and flow cytometry. TIGIT effect on AKI outcomes was studied with TIGIT knockout (TIGIT-KO) mice in ischemia reperfusion (IR) and cisplatin AKI models. Human kidney T cells from nephrectomy samples and single cell RNA sequencing (scRNA-Seq) data from the Kidney Precision Medicine Project were used to assess TIGIT's role in humans.
RESULTS
RNA-Seq and flow cytometry analysis of mouse kidney CD4+ T cells revealed increased expression of TIGIT after IR injury. Ischemic injury also increased TIGIT expression in human kidney T cells, and TIGIT expression was restricted to T/natural killer cell subsets in patients with AKI. TIGIT-expressing kidney T cells in wild type (WT) mice had an effector/central memory phenotype and proinflammatory profile at baseline and post-IR. Kidney regulatory T cells were predominantly TIGIT+ and significantly reduced post-IR. TIGIT-KO mice had significantly reduced kidney injury after IR and nephrotoxic injury compared with WT mice. scRNA-Seq analysis showed enrichment of genes related to oxidative phosphorylation and mTORC1 signaling in Th17 cells from TIGIT-KO mice.
CONCLUSIONS
TIGIT expression increases in mouse and human kidney T cells during AKI, worsens AKI outcomes, and is a novel therapeutic target for AKI.
Identifiants
pubmed: 36747315
doi: 10.1681/ASN.0000000000000063
pii: 00001751-202305000-00010
pmc: PMC10125646
doi:
Substances chimiques
Immune Checkpoint Proteins
0
Receptors, Immunologic
0
TIGIT protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-771Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK123342
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI133524
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK104662
Pays : United States
Organisme : NIH HHS
ID : S10 OD026859
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM124725
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–1423. doi: 10.1007/s00134-015-3934-7
doi: 10.1007/s00134-015-3934-7
Kurzhagen JT, Dellepiane S, Cantaluppi V, Rabb H. AKI: an increasingly recognized risk factor for CKD development and progression. J Nephrol. 2020;33(6):1171–1187. doi: 10.1007/s40620-020-00793-2
doi: 10.1007/s40620-020-00793-2
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52. doi: 10.1038/s41572-021-00284-z
doi: 10.1038/s41572-021-00284-z
Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338–1342. doi: 10.4049/jimmunol.1003081
doi: 10.4049/jimmunol.1003081
Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57. doi: 10.1038/ni.1674
doi: 10.1038/ni.1674
Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569–581. doi: 10.1016/j.immuni.2014.02.012
doi: 10.1016/j.immuni.2014.02.012
Kraus AK, Chen J, Edenhofer I, et al. The role of T cell costimulation via DNAM-1 in kidney transplantation. PLoS One. 2016;11(2):e0147951. doi: 10.1371/journal.pone.0147951
doi: 10.1371/journal.pone.0147951
Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769. doi: 10.1080/2162402x.2018.1466769
doi: 10.1080/2162402x.2018.1466769
Raphael I, Kumar R, McCarl LH, et al. TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma. Front Immunol. 2021;12:637146. doi: 10.3389/fimmu.2021.637146
doi: 10.3389/fimmu.2021.637146
Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13(1):211. doi: 10.1186/s12916-015-0455-8
doi: 10.1186/s12916-015-0455-8
Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–1700. doi: 10.2215/CJN.00990119
doi: 10.2215/CJN.00990119
Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi: 10.1371/journal.pbio.3000410
doi: 10.1371/journal.pbio.3000410
Rabb H, Ramirez G, Saba SR, et al. Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 1996;271(2):F408–F413. doi: 10.1152/ajprenal.1996.271.2.f408
doi: 10.1152/ajprenal.1996.271.2.f408
Liu M, Grigoryev DN, Crow MT, et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009;76(3):277–285. doi: 10.1038/ki.2009.157
doi: 10.1038/ki.2009.157
Ascon DB, Lopez-Briones S, Liu M, et al. Phenotypic and functional characterization of kidney-infiltrating lymphocytes in renal ischemia reperfusion injury. J Immunol. 2006;177(5):3380–3387. doi: 10.4049/jimmunol.177.5.3380
doi: 10.4049/jimmunol.177.5.3380
Lee SA, Noel S, Kurzhagen JT, et al. CD4(+) T cell-derived NGAL modifies the outcome of ischemic acute kidney injury. J Immunol. 2020;204(3):586–595. doi: 10.4049/jimmunol.1900677
doi: 10.4049/jimmunol.1900677
Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210. doi: 10.1093/nar/30.1.207
doi: 10.1093/nar/30.1.207
Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15. doi: 10.1186/s13059-017-1382-0
doi: 10.1186/s13059-017-1382-0
Tan Y, Cahan P. SingleCellNet: a computational tool to classify single cell RNA-Seq data across platforms and across species. Cell Syst. 2019;9(2):207.e2–213.e2. doi: 10.1016/j.cels.2019.06.004
doi: 10.1016/j.cels.2019.06.004
Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14(1):128. doi: 10.1186/1471-2105-14-128
doi: 10.1186/1471-2105-14-128
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database Hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi: 10.1016/j.cels.2015.12.004
doi: 10.1016/j.cels.2015.12.004
Martina MN, Noel S, Saxena A, et al. Double-Negative αβ T cells are early responders to AKI and are found in human kidney. J Am Soc Nephrol. 2016;27(4):1113–1123. doi: 10.1681/ASN.2014121214
doi: 10.1681/ASN.2014121214
Noel S, Martina MN, Bandapalle S, et al. T lymphocyte-specific activation of Nrf2 protects from AKI. J Am Soc Nephrol. 2015;26(12):2989–3000. doi: 10.1681/ASN.2014100978
doi: 10.1681/ASN.2014100978
Del Zotto G, Principi E, Antonini F, et al. Comprehensive phenotyping of peripheral blood T lymphocytes in healthy mice. Cytometry A. 2021;99(3):243–250. doi: 10.1002/cyto.a.24246
doi: 10.1002/cyto.a.24246
Ascon DB, Ascon M, Satpute S, et al. Normal mouse kidneys contain activated and CD3+CD4- CD8- double-negative T lymphocytes with a distinct TCR repertoire. J Leukoc Biol. 2008;84(6):1400–1409. doi: 10.1189/jlb.0907651
doi: 10.1189/jlb.0907651
Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194(1):325–333. doi: 10.4049/jimmunol.1400497
doi: 10.4049/jimmunol.1400497
Simon S, Voillet V, Vignard V, et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. J Immunother Cancer. 2020;8(2):e001631. doi: 10.1136/jitc-2020-001631
doi: 10.1136/jitc-2020-001631
Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125(5):2046–2058. doi: 10.1172/jci80445
doi: 10.1172/jci80445
Andreatta M, Corria-Osorio J, Muller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun. 2021;12(1):2965. doi: 10.1038/s41467-021-23324-4
doi: 10.1038/s41467-021-23324-4
Tibbitt CA, Stark JM, Martens L, et al. Single-cell RNA sequencing of the T helper cell response to house dust mites defines a distinct gene expression signature in airway Th2 cells. Immunity. 2019;51(1):169.e5–184.e5. doi: 10.1016/j.immuni.2019.05.014
doi: 10.1016/j.immuni.2019.05.014
Ding J, Smith SL, Orozco G, Barton A, Eyre S, Martin P. Characterisation of CD4+ T cell subtypes using single cell RNA sequencing and the impact of cell number and sequencing depth. Sci Rep. 2020;10(1):19825. doi: 10.1038/s41598-020-76972-9
doi: 10.1038/s41598-020-76972-9
Yang L, Zhu Y, Tian D, et al. Transcriptome landscape of double negative T cells by single-cell RNA sequencing. J Autoimmun. 2021;121:102653. doi: 10.1016/j.jaut.2021.102653
doi: 10.1016/j.jaut.2021.102653
Szabo PA, Levitin HM, Miron M, et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat Commun. 2019;10(1):4706. doi: 10.1038/s41467-019-12464-3
doi: 10.1038/s41467-019-12464-3
van der List ACJ, Litjens NHR, Klepper M, Betjes MGH. Expression of senescence marker TIGIT identifies polyfunctional donor-reactive CD4+ T cells preferentially lost after kidney transplantation. Front Immunol. 2021;12:656846. doi: 10.3389/fimmu.2021.656846
doi: 10.3389/fimmu.2021.656846
Basile DP, Ullah MM, Collet JA, Mehrotra P. T helper 17 cells in the pathophysiology of acute and chronic kidney disease. Kidney Res Clin Pract. 2021;40(1):12–28. doi: 10.23876/j.krcp.20.185
doi: 10.23876/j.krcp.20.185
Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest. 2001;108(9):1283–1290. doi: 10.1172/jci200112080
doi: 10.1172/jci200112080
Gandolfo MT, Jang HR, Bagnasco SM, et al. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009;76(7):717–729. doi: 10.1038/ki.2009.259
doi: 10.1038/ki.2009.259
de la Cruz Lopez KG, Toledo Guzman ME, Sanchez EO, Garcia Carranca A. mTORC1 as a regulator of mitochondrial functions and a therapeutic target in cancer. Front Oncol. 2019;9:1373. doi: 10.3389/fonc.2019.01373
doi: 10.3389/fonc.2019.01373
Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol. 2008;180(7):4476–4486. doi: 10.4049/jimmunol.180.7.4476
doi: 10.4049/jimmunol.180.7.4476
Fuhrman CA, Yeh WI, Seay HR, et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol. 2015;195(1):145–155. doi: 10.4049/jimmunol.1402381
doi: 10.4049/jimmunol.1402381
Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062. doi: 10.1172/jci81187
doi: 10.1172/jci81187
de Lima MHF, Hiroki CH, de Fatima Borges V, et al. Sepsis-induced immunosuppression is marked by an expansion of a highly suppressive repertoire of FOXP3 +T regulatory cells-expressing TIGIT. J Infect Dis. 2022;225(3):531–541. doi: 10.1093/infdis/jiab405
doi: 10.1093/infdis/jiab405
Luo Q, Deng Z, Xu C, et al. Elevated expression of immunoreceptor tyrosine-based inhibitory motif (TIGIT) on T lymphocytes is correlated with disease activity in rheumatoid arthritis. Med Sci Monit. 2017;23:1232–1241. doi: 10.12659/msm.902454
doi: 10.12659/msm.902454
Mao L, Hou H, Wu S, et al. TIGIT signalling pathway negatively regulates CD4(+) T cell responses in systemic lupus erythematosus. Immunology. 2017;151(3):280–290. doi: 10.1111/imm.12715
doi: 10.1111/imm.12715